IL-21 enhances antitumor responses without stimulating proliferation of malignant T cells of patients with Sézary syndrome

Journal of Investigative Dermatology

Volumn 128, Issue 2, 2008, Pages 473-480

  Yoon, Jessica S ^a   Newton, Sarah M ^a   Wysocka, Maria ^a   Troxel, Andrea B ^a   Hess, Stephen D ^a   Richardson, Stephen K ^a   Lin, Julie H ^a   Benoit, Bernice M ^a   Kasprzycka, Monika ^a   Wasik, Mariusz A ^a   Rook, Alain H ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 21;

ADAPTIVE IMMUNITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; NATURAL KILLER T CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEZARY SYNDROME; T CELL LYMPHOMA; T LYMPHOCYTE;

EID: 38149088718     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/sj.jid.5701027     Document Type: Article

References (44)

1. Abrams JT, Lessin S, Ghosh SK, Ju W, Vonderheid EC, Nowell P et al. (1991) A clonal CD4-positive T-cell line established from the blood of a patient with Sezary syndrome. J Invest Dermatol 96:31-7
2. Alves NL, Arosa FA, van Lier RA (2005) IL-21 sustains CD28 expression on IL-15-activated human naive CD8+ T cells. J Immunol 175:755-62
3. Bouaziz JD, Ortonne N, Giustiniani J, Schiavon V, Huet D, Bagot M et al. (2005) Circulating natural killer lymphocytes are potential cytotoxic effectors against autologous malignant cells in Sezary syndrome patients. J Invest Dermatol 125:1273-8
4. Brady J, Hayakawa Y, Smyth MJ, Nutt SL (2004) IL-21 induces the functional maturation of murine NK cells. J Immunol 172:2048-58
5. Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T et al. (2001) Human natural killer cells: a unique innate immunoregulatory role for the CD56 (bright) subset. Blood 97:3146-51
6. Curti BD (2006) Immunomodulatory and antitumor effects of interleukin-21 in patients with renal cell carcinoma. Expert Rev Anticancer Ther 6:905-9
7. Diamandidou E, Cohen PR, Kurzrock R (1996) Mycosis fungoides and Sezary syndrome. Blood 88:2385-409
8. DiCarlo E, Comes A, Oreng AM, Rosso O, Meazza R, Musiani P et al. (2004) IL-21 induces tumor rejection by specific CTL and IFN-gamma-dependent CXC chemokines in syngeneic mice. J Immunol 172:1540-7
9. Fehniger TA, Shah MH, Turner MJ, VanDeusen JB, Whitman SP, Cooper MA et al. (1999) Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J Immunol 162:4511-20
10. Jin H, Carrio R, Yu A, Malek TR (2004) Distinct activation signals determine whether IL-21 induces B cell costimulation, growth arrest, or Bim-dependent apoptosis. J Immunol 173:657-65
11. Kaplan EH, Rosen ST, Norris DB, Roenigk HJ, Saks SR, Bunn PAJ (1990) Phase II study of recombinant human interferon gamma for treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst 82:208-12
12. Kasaian M, Whitters MJ, Carter LL, Lowe LD, Jussif JM, Deng B et al. (2002) IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. Immunity 16:559-69
13. Kishida T, Asada H, Itokawa Y, Cui FD, Shin-Ya M, Gojo S et al. (2003) Interleukin (IL)-21 and IL-15 genetic transfer synergistically augments therapeutic antitumor immunity and promotes regression of metastatic lymphoma. Mol Ther 8:552-8
14. Kranzer K, Bauer M, Lipford GB, Heeg K, Wagner H, Lang R (2000) CpG-oligodeoxynucleotides enhance T-cell receptor-triggered interferon-gamma production and up-regulation of CD69 via induction of antigen-presenting cell-derived interferon type I and interleukin-12. Immunology 99:170-8
15. Kupper TS, Fuhlbrigge RC (2004) Immune Surveillance in the skin: mechanisms and clinical consequences. Nat Rev Immunol 4:211-22
16. Lanier LL, Le AM, Civin CI, Loken MR, Phillips JH (1986) The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol 136:4480-6
17. Leonard WJ, Spolski R (2005) Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiation. Nat Rev Immunol 5:688-98
18. Ma HL, Whitters MJ, Konz RF, Senices M, Young DA, Grusby MJ et al. (2003) IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-gamma. J Immunol 171:608-15
19. McGinnis KS, Ubriani R, Newton S, Junkins-Hopkins JM, Vittorio CC, Kim EJ et al. (2005) The addition of interferon gamma to oral bexarotene therapy with photopheresis for Sezary syndrome. Arch Dermatol 141:1176-8
20. Mehta DS, Wurster AL, Whitters MJ, Young DA, Collins M, Grusby MJ (2003) IL-21 induces the apoptosis of resting and activated primary B cells. J Immunol 170:4111-8
21. Moroz A, Eppolito C, Li Q, Tao J, Clegg CH, Shrikant PA (2004) IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21. J Immunol 173:900-9
22. Murphy GF (1988) Cutaneous T-cell lymphoma. Adv Pathol 1:131-56
23. Ozaki K, Spolski R, Ettinger R, Kim HP, Wang G, Qi CF et al. (2004) Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J Immunol 173:5361-71
24. Parrish-Novak J, Dillon SR, Nelson A, Hammond A, Sprecher C, Gross JA et al. (2000) Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 408:57-63
25. Parrish-Novak J, Foster DC, Holly RD, Clegg CH (2002) Interleukin-21 and the IL-21 receptor: novel effectors of NK and T cell responses. J Leukoc Biol 72:856-63
26. Rook AH, Heald P (1995) The immunopathogenesis of cutaneous T-cell lymphoma. Hematol Oncol Clin N Am 9:997-1010
27. Rook AH, Kubin M, Cassin M, Vonderheid EC, Vowels BR, Wolfe JT et al. (1995) IL-12 reverses cytokine and immune abnormalities in Sezary syndrome. J Immunol 154:1491-8
28. Rook AH, Suchin KR, Kao DM, Yoo EK, Macey WH, DeNardo BJ et al. (1999a) Photopheresis: clinical applications and mechanism of action. J Investig Dermatol Symp Proc 4:85-90
29. Rook AH, Wood GS, Yoo EK, Elenitsas R, Kao DM, Sherman ML et al. (1999b) Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 94:902-8
30. Rook AH, Yoo EK, Grossman DJ, Kao DM, Fox FE, Niu Z (1998) Use of biological response modifiers in the treatment of cutaneous T-cell lymphoma. Curr Opin Oncol 10:170-4
31. Sgonc R, Boeck G, Dietrich H, Gruber J, Recheis H, Wick G (1994) Simultaneous determination of cell surface antigens and apoptosis. Trends Genet 10:40-2
32. Street SE, Cretney E, Smyth MJ (2001) Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood 97:192-7
33. Suchin KR, Cucchiara AJ, Gottleib SL, Wolfe JT, DeNardo BJ, Macey WH et al. (2002) Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: a 14-year experience at a single institution. Arch Dermatol 138:1054-60
34. Sun S, Zhang X, Tough DF, Sprent J (1998) Type I interferon-mediated stimulation of T cells by CpG DNA. J Exp Med 188:2335-42
35. Ueda MIK, Imura A, Koga H, Masakatsu H, Uchiyama T (2004) Expression of functional interleukin-21 receptor on adult T-cell leukaemia cells. Br J Haematol 128:169-76
36. Ugai S, Shimozato O, Kawamura K, Wang YQ, Yamaguchi T, Saisho H et al. (2003a) Expression of the interleukin-21 gene in murine colon carcinoma cells generates systemic immunity in the inoculated hosts. Cancer Gene Ther 10:187-92
37. Ugai S, Shimozato O, Yu L, Wang YQ, Kawamura K, Yamamoto H et al. (2003b) Transduction of the IL-21 and IL-23 genes in human pancreatic carcinoma cells produces natural killer cell-dependent and -independent antitumor effects. Cancer Gene Ther 10:771-8
38. Vittorio CC, Junkins-Hopkins JM, McGinnis KS, Shapiro M, Wysocka M, Zaki MH et al. (2002) New biological response modifiers in the treatment of cutaneous T-cell lymphoma. Recent Res Cancer Res 160:321-8
39. Wang G, Tschoi M, Spolski R, Lou Y, Ozaki K, Feng C et al. (2003) In vivo antitumor activity of interleukin 21 mediated by natural killer cells. Cancer Res 63:9016-22
40. White L, Krishnan S, Strbo N, Liu H, Kolber MA, Lichtenheld MG et al. (2006) Differential effects of IL-21 and IL-15 on perforin expression, lysosomal degranulation and proliferation in CD8 T cells of patients infected with human immunodeficiency virus-1 (HIV). Blood 109:3873-80
41. Wysocka M, Benoit BM, Newton S, Azzoni L, Montaner IJ, Rook AH (2004) Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG-oligodeoxynucleotides and IL-15. Blood 104:4142-9
42. Wysocka M, Zaki MH, French LE, Chehimi J, Shapiro M, Everetts SE et al. (2002) Sezary syndrome patients demonstrate a defect in dendritic cell populations: effects of CD40 ligand and treatment with GM-CSF on dendritic cell numbers and the production of cytokines. Blood 100:3287-94
43. Yoo EK, Cassin M, Lessin SR, Rook AH (2001) Complete molecular remission during biologic response modifier therapy for Sezary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity. J Am Acad Dermatol 45:208-16
44. Zeng R, Spolski R, Finkelstein SE, Oh S, Kovanen PE, Hinrichs CS et al. (2005) Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J Exp Med 201:139-48